MPN-1 is under clinical development by Cellworks Group and currently in Phase I for Myeloproliferative Disorders. According to GlobalData, Phase I drugs for Myeloproliferative Disorders have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MPN-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MPN-1 overview

Small molecule is under development for the treatment of myeloproliferative neoplasms (MPN). The drug candidate is a new chemical entity that is being developed based on biosimulation technology.

Cellworks Group overview

Cellworks Group (Cellworks) is a biotechnology company that develops precision medicine for the treatment of oncology and immunology. The company’s product portfolio includes Cellworks Singula and Ventura. It is also advancing its pipeline products in the areas of oncology, immunology, dermatology and infectious diseases. Cellworks employs Therapy Response Index and Cellworks Biosimulation Platform for developing its products. The company works in collaborations with research centers for future development of its pipeline products. It has research and development facility in India. Cellworks is headquartered in South San Francisco, California, the US.

For a complete picture of MPN-1’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.